Indications of Tazemetostat
Tazemetostat is a methyltransferase inhibitor indicated for the treatment of:
Adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.
Adult patients with relapsed or refractory follicular lymphoma whose tumors are EZH2 mutation‑positive as detected by an FDA‑approved test, and who have received at least 2 prior systemic therapies.
Adult patients with relapsed or refractory follicular lymphoma for whom no satisfactory alternative treatment options exist.
These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials.
Important Precautions
Monitoring Requirements
Obtain complete blood count, liver function, and renal function tests before and regularly during treatment.
Prompt medical attention is required for fever, abnormal bleeding, or symptoms of infection.
Drug Interactions
Avoid concomitant use with strong CYP3A inhibitors (e.g., clarithromycin) or inducers (e.g., rifampicin), which may alter efficacy or toxicity.
Concomitant use with anticoagulants may increase bleeding risk.
Special Populations
Pregnant and breastfeeding women: Contraindicated. Patients of reproductive potential must use effective contraception.
Geriatric patients: No dose adjustment is needed, but enhanced monitoring is recommended.
Contraindications
Hypersensitivity to tazemetostat or any of its ingredients.
Pregnancy (may cause fetal harm).
Severe hepatic impairment (Child‑Pugh Class C) is not recommended.
Storage Conditions
Store at room temperature between 20°C and 25°C.
Protect from moisture and light.
Keep out of reach of children.
General Administration Advice
Tazemetostat must be used under the guidance of a physician.Do not adjust the dose or discontinue treatment without medical supervision.Close follow‑up is required during treatment to manage adverse reactions.Attention should also be paid to the importance of genetic testing and individualized therapy.
